Table 1. Clinico-pathological features and biomarker profile of the series.
| Parameter | na | na (%) | |
| IBC | |||
| Tumour grade | 601 | ||
| 1 | 82 (14) | ||
| 2 | 307 (51) | ||
| 3 | 212 (35) | ||
| Tubule formation score | 583 | ||
| 1 | 31 (5) | ||
| 2 | 74 (13) | ||
| 3 | 478 (82) | ||
| Nuclear pleomorphism score | 583 | ||
| 1 | 7 (1) | ||
| 2 | 287 (49) | ||
| 3 | 289 (50) | ||
| Mitotic count score | 583 | ||
| 1 | 367 (3) | ||
| 2 | 103 (18) | ||
| 3 | 113 (19) | ||
| Histological type | 661 | ||
| Ductal | 509 (77) | ||
| Lobular | 102 (15) | ||
| Mucinous | 14 (2) | ||
| Mixed ductal and lobular | 10 (2) | ||
| Tubular | 5 (1) | ||
| Medullary | 5 (1) | ||
| Microinvasive ductal | 5 (1) | ||
| Apocrine | 3 (0.5) | ||
| Ductal and papillary or cribriform | 3(0.5) | ||
| Invasive papillary | 2 (0.3) | ||
| Other | 3 (0.5) | ||
| Tumour size (mm) | 625 | ||
| ≤20 | 239 (38) | ||
| 21–50 | 314 (50) | ||
| >50 | 72 (12) | ||
| Nodal status | 596 | ||
| Positive | 302 (51) | ||
| Negative | 294 (49) | ||
| Number of positive lymph nodes | 596 | ||
| 0 | 294 (49) | ||
| 1–3 | 165 (28) | ||
| 4–9 | 88 (15) | ||
| ≥10 | 49 (8) | ||
| Lymphovascular invasion | 386 | ||
| Present | 203 (53) | ||
| Absent | 174 (45) | ||
| Probable | 9 (2) | ||
| Number of events | 663 | ||
| Alive, no disease | 301 (45) | ||
| Alive, LR disease | 191 (29) | ||
| Alive, distant metastases | 58 (9) | ||
| Dead with disease progression | 87 (13) | ||
| Dead with no disease progression | 26 (4) | ||
| ER | 522 | ||
| Positive | 344 (66) | ||
| Negative | 178 (34) | ||
| PR | 534 | ||
| Positive | 297 (56) | ||
| Negative | 237 (44) | ||
| HER2 | 602 | ||
| Positive | 85 (14) | ||
| Negative | 517 (86) | ||
| BCL2 | 534 | ||
| Positive | 290 (54) | ||
| Negative | 244 (46) | ||
| Ki67 | 540 | ||
| Positive | 163 (30) | ||
| Negative | 377 (70) | ||
| EGFR | 527 | ||
| Positive | 77 (14) | ||
| Negative | 450 (85) | ||
| CK5/6 | 463 | ||
| Positive | 42 (9) | ||
| Negative | 421 (91) | ||
| CK14 | 444 | ||
| Positive | 94 (21) | ||
| Negative | 350 (79) | ||
| p53 | 523 | ||
| Positive | 105 (20) | ||
| Negative | 418 (80) | ||
| DCIS associated with IBC | 397 | ||
| Grade | 339 | ||
| Low | 13 (4) | ||
| Intermediate | 137 (40) | ||
| High | 189 (56) | ||
| Size b (mm) | 59 | ||
| Median | 38 | ||
| Range | 2–236 | ||
| Pure DCIS | 83 | ||
| Grade | 54 | ||
| Low | 7 (13) | ||
| Intermediate | 21 (39) | ||
| High | 26 (48) | ||
| Size (mm) | 41 | ||
| Median | 15 | ||
| Range | 0.8–83 | ||
| Number of events | 81 | ||
| Alive, no disease | 63 (78) | ||
| Alive, LR disease | 4 (5) | ||
| Alive, distant metastases | 1 (1) | ||
| Dead with disease progression | 9 (11) | ||
| Dead with no disease progression | 4 (5) |
a no. of cases for which data is available.
b whole tumour measurement is given in cases if it differs from the size of the IBC.
LR: locoregional.